Wu Zhou Shi

Researchers are evaluating the effects of reduced-dose radiotherapy (40.2Gy) compared to conventional-dose radiotherapy (49.2Gy) on low-risk target volumes in patients with chemosensitive intermediate-stage nasopharyngeal carcinoma. This phase 3 trial includes patients who have responded well to induction chemotherapy and whose plasma EBV-DNA levels have dropped to zero or below detection limits. The goal is to see if lowering the radiation dose can maintain treatment effectiveness while reducing side effects and improving quality of life. Participants will be randomly assigned to receive either reduced-dose or conventional-dose radiotherapy targeting the CTV2 area, while both groups receive the full course of PD-1 monoclonal antibody immunotherapy. The immunotherapy consists of 12 courses given every three weeks, starting with induction chemotherapy and continuing through radiotherapy and post-radiotherapy maintenance. Induction chemotherapy includes three cycles of gemcitabine and cisplatin or alternative drugs, administered intravenously. Throughout the study, patients will be closely monitored for progression-free survival and the occurrence of significant adverse events over three years. Researchers will assess survival outcomes, side effects, and quality of life differences between the two groups. Regular evaluations include imaging, laboratory tests, and clinical assessments to ensure patient safety and treatment effectiveness during the entire follow-up period.

Researchers are evaluating the safety and therapeutic effects of nimotuzumab combined with induction chemotherapy, chemoradiation, and adjuvant therapy in patients with locoregionally advanced nasopharyngeal carcinoma. Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor and has been approved for use in several cancers including squamous cell carcinoma of the head and neck. This multi-center, randomized controlled trial aims to determine how well this combination treatment works compared to standard therapies. Participants will receive nimotuzumab alongside induction chemotherapy with gemcitabine and cisplatin. Nimotuzumab is administered weekly for six cycles during induction chemotherapy, then weekly concurrent with intensity-modulated radiotherapy (IMRT). After chemoradiation, nimotuzumab is given every three weeks for eight cycles as adjuvant therapy. The radiation therapy involves definitive IMRT delivered in 30 to 33 fractions over several weeks. The control group will receive nimotuzumab weekly concurrent with IMRT without induction chemotherapy or adjuvant therapy. Throughout the study, participants will be closely monitored through laboratory tests and clinical assessments to evaluate treatment safety and effectiveness. The primary outcome measure is overall survival at five years. Patients must sign informed consent and comply with scheduled visits, treatments, and testing. The total participation spans the treatment period plus long-term follow-up to assess survival outcomes and monitor adverse effects.

Researchers are evaluating the effectiveness of adding PD-1 treatment to chemo-radiotherapy for patients with high-risk nasopharyngeal carcinoma. This phase 3, multicenter, open-label, randomized clinical trial compares the combined approach with chemo-radiotherapy alone to see if it can better reduce disease progression and improve survival outcomes. Participants are randomly assigned to one of two groups: one receiving camrelizumab plus chemo-radiotherapy, and the other receiving chemo-radiotherapy alone. The camrelizumab group receives 200 mg of the drug intravenously every three weeks for two cycles during radiotherapy and continues treatment for one year after radiotherapy. Both groups undergo induction chemotherapy with gemcitabine and cisplatin, concurrent cisplatin chemotherapy during radiotherapy, and intensity-modulated radiotherapy (IMRT) targeting specific regions. During the study, participants are monitored for progression-free survival over three years. Researchers assess treatment safety and effectiveness, comparing outcomes between the two groups. Participants undergo regular clinical evaluations and laboratory tests to track their response and any side effects. The total participation duration includes induction chemotherapy, concurrent therapy, and follow-up for outcome measurement.

This research aims to evaluate the diagnostic accuracy of a new Epstein-Barr virus (EBV) C promoter methylation detection kit in patients suspected of having nasopharyngeal carcinoma. Participants will be those showing symptoms or signs of nasopharyngeal carcinoma or related conditions, including those testing positive for EBV antibodies or DNA, and those needing differential diagnosis from other head and neck cancers. The study seeks to determine how well this methylation detection method can identify nasopharyngeal carcinoma compared to current diagnostic methods. All participants will undergo diagnostic tests that include detecting VCA-IgA, EBNA1-IgA, and EBV-DNA markers. Additionally, nasopharyngeal swab samples will be collected to analyze the methylation status of the EBV C promoter. A confirmatory biopsy will be performed for all patients to establish a definitive diagnosis and to compare the effectiveness of the new detection kit with standard diagnostic procedures. Throughout the study, researchers will assess the sensitivity, specificity, and agreement of the EBV C promoter methylation test compared to final biopsy results, with follow-up lasting up to four weeks from enrollment to diagnosis. This comprehensive diagnostic evaluation includes multiple assays and methylation analysis to better understand the kit's performance in a clinical setting and improve nasopharyngeal carcinoma diagnosis.

Stroke is the second leading cause of death worldwide, with ischemic stroke being the most common type. The current best treatment for acute ischemic stroke is intravenous thrombolysis using recombinant tissue plasminogen activator (rt-PA) given within 4.5 hours of symptom onset. However, some patients experience stroke progression or early blood vessel reocclusion after thrombolysis, which worsens neurological function and outcomes. This is believed to be caused by increased platelet activation after thrombolysis, which peaks within the first 2 hours. This clinical trial is testing whether starting oral aspirin early after intravenous thrombolysis can improve functional outcomes without causing more bleeding problems. Patients are randomly assigned to receive either 300 mg aspirin tablets or matching placebo tablets as soon as possible after enrollment. If swallowing is difficult, tablets can be crushed and given through a nasogastric tube. Both groups receive best medical management according to guidelines. The study is a Phase 3, multicenter, randomized, placebo-controlled trial. Participants will be followed for 90 days after stroke to measure their functional recovery using the modified Rankin scale (mRS). Researchers will check if patients have a good outcome defined as an mRS score of 0 or 1 at 90 days. During the study, patients undergo assessments including neurological exams and imaging to confirm eligibility and monitor safety. The trial aims to determine if early aspirin treatment after thrombolysis is safe and can help prevent neurological decline and improve recovery.

This is a multicenter, randomized, double-blind, placebo-controlled, exploratory Phase II clinical trial. The goal of this clinical trial is to assess the safety and efficacy of edaravone dexborneol sublingual tablets for post-stroke cognitive impairment in patients with acute ischemic stroke. Participants will be required to receive 24 weeks treatment of edaravone dexborneol sublingual tablets or placebo during this study. The safety and efficacy endpoints will be compared in the patients with edaravone dexborneol sublingual tablets or placebo.

Researchers are evaluating the effects of immunonutrition compared to standard nutrition on reducing oral mucositis in patients with locally advanced nasopharyngeal carcinoma undergoing chemoradiotherapy. Oral mucositis is a common and often severe side effect causing pain, swallowing difficulties, and malnutrition, which can delay treatment and worsen patients' quality of life and prognosis. This study aims to determine whether immunonutritional therapy can improve outcomes and reduce the severity of oral mucositis in these patients. Participants are randomly assigned to receive either enteral immunonutrition or standard enteral nutrition. The immunonutrition group receives Oral Impact®, 250 ml twice daily starting 5 days before radiotherapy and continuing until the end of radiotherapy. The standard nutrition group is given ENSURE®, 250 ml three times daily prepared by mixing powder with water. Both nutritional supplements are designed to provide calories, with immunonutrition also targeting immune regulation and anti-inflammatory effects. Throughout the 7-week study period, researchers will monitor the incidence of severe oral mucositis as the primary outcome. Participants undergo clinical evaluations including laboratory tests to assess organ function and nutritional status. The study also tracks patients' adherence to the nutrition plans and collects data on treatment tolerance, quality of life, and any adverse effects to evaluate the safety and effectiveness of immunonutrition compared to standard care.

Researchers are studying the relationship between Epstein-Barr Virus (EBV) antibody levels and the risk of developing various cancers in Southern China. This study aims to determine if EBV is linked not only to known EBV-related cancers like lymphomas, nasopharyngeal carcinoma, and stomach cancer but also to other types of cancer. The research seeks to understand the overall cancer burden caused by EBV in this region. Participants have their EBV antibody levels tested at the start of the study using several tests including VCA-IgA and EBNA1-IgA. After enrollment, they are followed annually to monitor cancer occurrence, their health status, and any changes in residence. This ongoing monitoring helps gather data on the connection between EBV antibodies and cancer development over time. During the study, participants will undergo EBV antibody testing and annual follow-up checks for up to 10 years to track new cancer cases. Researchers will collect information on overall cancer risk and specific cancer types linked to EBV. The primary outcome measured is cancer incidence over a 10-year period, allowing long-term observation of participants' health related to EBV exposure.

Researchers are evaluating treatment options for patients with locally advanced nasopharyngeal carcinoma (NPC), focusing on improving survival while reducing treatment side effects. The study compares induction chemotherapy followed by radiotherapy alone versus induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) using intensity-modulated radiation therapy (IMRT), a technique that has improved local tumor control in recent years. The trial is a randomized Phase III study aiming to clarify the benefits of these approaches in the context of modern radiation techniques. Participants will be randomly assigned to one of two groups. Both groups receive induction chemotherapy with gemcitabine and cisplatin every three weeks for three cycles. The experimental group then receives IMRT alone, while the comparator group receives IMRT plus concurrent cisplatin chemotherapy given every three weeks for three cycles during radiation treatment. Radiation is delivered five days a week for 6 to 7 weeks, targeting the primary tumor and affected lymph nodes with doses above 66 Gy and 50 Gy, respectively. During the study, participants will be closely monitored through blood tests and clinical assessments to ensure safety and treatment adherence. Researchers will track progression-free survival over three years to evaluate effectiveness. The study includes patients aged 18 to 65 years with specific tumor staging and good overall health. The total duration of treatment spans the induction chemotherapy and radiotherapy phases, with long-term outcome follow-up planned.

Chronic subdural hematoma (CSDH) is a common neurosurgical condition where fluid builds up between the brain coverings, causing brain compression and neurological problems. The best treatment method is still uncertain, and this trial aims to compare two surgical approaches to find the most effective one. Neuroendoscopy-assisted drainage allows surgeons to directly see and remove the hematoma more thoroughly compared to the conventional burr-hole drainage method, which may reduce recurrence and drainage time. The study compares neuroendoscopy-assisted hematoma drainage with traditional burr-hole drainage. Both procedures involve drilling a single burr hole at the thickest part of the hematoma as seen on CT scan. In the neuroendoscopy group, a bone flap is created and a neuroendoscope guides thorough irrigation and evacuation of the hematoma, followed by drainage for up to 48 hours. In the burr-hole group, the hematoma cavity is irrigated until clear and drainage is also maintained for up to 48 hours after surgery. Participants will be evaluated before and after surgery, with clinical symptoms and imaging confirming CSDH diagnosis. The main outcome measured is the recurrence rate of hematoma within three months after surgery. Continuous monitoring will occur until drainage ends or the tube is removed. Follow-up visits will assess neurological status and recovery over three months, ensuring safety and treatment effectiveness throughout the study period.